Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson’s disease
Martin Gorges, Barbara Kuntz, Kelly del Tredici, Daniel Schmidt, Hans-Peter Müller, Albert Ludolph, Luc Dupuis, Jan Kassubek

To cite this version:

HAL Id: inserm-03376294
https://inserm.hal.science/inserm-03376294
Submitted on 13 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
to have an active role in the termination of synaptic dopamine signals and also in the release of dopamine. Thus, DAT imaging could reflect synaptic dopamine levels or DAT expression, a hypothesis which should be investigated in detail in future imaging studies.

To conclude, there appears to be no correlation between striatal DAT binding and the number of post-mortem striatal axons or nigral neurons. The precise mechanism of changes in DAT binding signal in PD remains to be elucidated, but the amount of synaptic dopamine may have a key role. These results do not support the use of DAT imaging as a surrogate marker for striatal axonal loss.

Acknowledgments: The staff of the Department of Pathology and the Department of Nuclear Medicine at Turku University Hospital is gratefully acknowledged. We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

References

The hypothalamus plays a pivotal integrative role in a broad spectrum of body functions, including energy metabolism\(^1\)\(^2\) and circadian control.\(^3\) Pathological changes in the hypothalamus in Parkinson’s disease (PD) were noted decades ago, including early observations by Fritz Jakob Lewy\(^4\) and the work by Braak and colleagues, who reported that the PD-associated pathology targets the hypothalamic tuberomammillary and ventromedial nuclei in an early symptomatic phase.\(^5\)\(^6\) In addition, the importance of a dopaminergic contribution to a broad spectrum of nonmotor symptoms is supported by dopamine dysfunction in the hypothalamus in PD.\(^7\)

Breen and colleagues recently reported hypothalamic volume loss in a small PD cohort.\(^8\) Other neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD), are also known to be associated with metabolic changes in correlation with severe atrophy of the hypothalamus\(^10\)\(^11\). These findings suggest that identification of pathways leading to perturbed energy balance might provide novel therapeutic targets.\(^12\) We tested the hypothesis of whether hypothalamic involvement in PD could be shown by volumetric hypothalamus mapping using a well-established manual segmentation procedure based on high-resolution MRI. A MRI-based quantitative analysis of the hypothalamic volume was performed in >200 individuals with PD compared with matched healthy non-PD individuals.

### Materials and Methods

#### Study Population

The study population was organized into a prospective and a retrospective cohort, including a total of 362 participants including non-PD individuals. All 232 individuals with PD were idiopathic (sporadic) PD cases without any known PD-associated gene mutations. Details on the inclusion and exclusion criteria for both PD cohorts are provided in the Supplementary Material.

#### Prospective cohort

The study was approved by the Ethical Committee of the University of Ulm, Ulm, Germany (reference 159/17), and all participants provided written informed consent. All individuals with PD underwent standardized clinical-neurological examinations and were diagnosed according to the UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria.\(^13\) All measurements were performed in the ON state. All non-PD individuals (n = 30) were well-matched healthy elderly volunteers without a history of neurological or psychiatric disease or other medical conditions. Participants’ demographics and clinical data are summarized in Table 1. Imaging data were acquired on a 3 Tesla MRI scanner (Prisma Siemens Medical, Erlangen, Germany) using a high-resolution 3-D T\(_1\)-weighted magnetization-prepared gradient echo image (MPRAGE) sequence. Whole-brain coverage comprised 192 sagittal slices, no gap, 1.0 × 1.0 × 1.0 mm\(^3\) voxels, 240 × 192 × 256 matrix, TE, 2.05 milliseconds; TR, 2300 milliseconds; flip angle, 9\(^\circ\).

#### Retrospective cohort

All participants provided written informed consent as above (reference 88/11). Hypothalamus volumes from a large representative PD cohort (n = 202, 68 ± 11 years, 6.7 ± 6.3 years of disease duration; UPDRS III score, 24 ± 13) and matched non-PD individuals (n = 100,

### Table 1. Demographic and clinical data

<table>
<thead>
<tr>
<th>Variable</th>
<th>Individuals with PD (n = 30)</th>
<th>Healthy non-PD individuals (n = 30)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.7 ± 12.0 (36.2–81.6)</td>
<td>60.2 ± 13.0 (36.1–79.5)</td>
<td>0.43(^a)</td>
</tr>
<tr>
<td>Sex (male:female)</td>
<td>22:8</td>
<td>17:13</td>
<td>0.28(^b)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>7.9 ± 3.8 (1.4–17.8)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>PD phenotype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tremor dominant</td>
<td>10 (33.3%)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Akinesic-rigid</td>
<td>7 (23.3%)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Gait disturbance</td>
<td>1 (3.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed</td>
<td>12 (40.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPDRS III</td>
<td>16.7 ± 4.6 (10.0–30.0)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>MoCA(^c)</td>
<td>24.9 ± 4.9 (6.0–30.0)</td>
<td>27.2 ± 2.2 (21.0–30.0)</td>
<td>0.030(^c)</td>
</tr>
<tr>
<td>ESS(^d)</td>
<td>7.8 ± 4.5 (3.0–20.0)</td>
<td>5.7 ± 3.0 (1.0–13.0)</td>
<td>0.122(^c)</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>28.2 ± 4.0 (21.6–39.0)</td>
<td>26.6 ± 3.7 (21.8–35.5)</td>
<td>0.100(^c)</td>
</tr>
<tr>
<td>Education</td>
<td>13.0 ± 2.3 (8.0–16.0)</td>
<td>14.6 ± 2.9 (9.0–20.0)</td>
<td>0.052(^c)</td>
</tr>
</tbody>
</table>

Values are given as mean ± standard deviation (min-max).
\(^a\) t tests (2-sample, unpaired, unequal variances).
\(^b\) Fisher’s exact test.
\(^c\) Mann-Whitney U test.
\(^d\) Epworth Sleepiness Scale.\(^16\)
\(^e\) Montreal Cognitive Assessment.\(^19\)
\(^f\) Body mass index.
na, not applicable.
64 ± 9 years) were retrospectively analyzed using the identical segmentation procedure and volumetric analysis pipeline (see Imaging Methods). Imaging data were acquired at a 1.5 Tesla clinical MRI scanner (Symphony, Siemens Medical, Erlangen, Germany) using an MPRAGE sequence (144 sagittal slices, no gap, 1.0 × 1.2 × 1.0 mm³ voxels, 256 × 192 × 256 matrix, TE, 4.2 milliseconds; TR, 1600 milliseconds).

MR-Based Hypothalamus Segmentation

Coronal slices were used for manual delineation of the hypothalamus using a well-established landmark-based procedure11 (Supplementary Fig. 1), which is implemented in the Tensor Imaging and Fiber Tracking (TIFT) software package.14 Prior to hypothalamus delineation, the following steps were performed: (1) rigid brain normalization, (2) spatial up-sampling into a study-specific grid (in-plane resolution of 62.5 × 62.5 μm², slice thickness of 0.5 mm) to improve the accuracy in identifying landmarks and hypothalamic borders, and (3) manual delineation of the left and right hemispheric hypothalamus. In particular, rigid body normalization was performed along the anterior commissure (AC) – posterior commissure (PC) axis such that the coronal cutting plane was perpendicular to the AC–PC axis.

The hypothalamus was manually delineated, as described previously11 and shown in the Supplementary Figure. The optical tract was excluded from all slices (Supplementary Fig. 1b–i). Prior to the analysis, all data sets were randomized such that the raters were blinded to all demographic and clinical features. This delineation procedure is robust and achieves a high level of reproducibility, as indicated by an intra- and interrater reliability analysis in a subsample of 12 × 3 = 36 randomized data sets. The coefficient of variation (CV) was CV < 4% for 2 raters; the intraclass correlation coefficient between the 2 raters was r > 0.9; both can be safely accepted as robust and highly reproducible.

Volumetric Analysis

Intracranial volume as an important covariate for volumetric analyses was determined with the Freesurfer image analysis suite (V.6.0.0; http://surfer.nmr.mgh.harvard.edu/). Given the distinct structural connectivity and histopathologically confirmed involvement of the hypothalamus,6 we performed anterior-posterior

---

**FIG. 1.** Volumetric analysis of the hypothalamus in Parkinson’s disease (PD). (a) Volumes of the hypothalamus did not differ between PD and non-PD individuals. (b) Slice volumetric analysis provided as mean ± SD of 20 coronal section spanning from the most anterior to the most posterior part of the hypothalamus indicated that the volumes of the coronal slices did not differ between PD (blue error bars) and non-PD individuals (black); t test P > 0.05. (c, d) Retrospective volumetric analysis from a large cohort of PD and non-PD individuals revealed similar results indicating no significant differences in hypothalamic volumes for (c) the total hypothalamus and (d) at the single coronal slice level. [Color figure can be viewed at wileyonlinelibrary.com]
segmentation using a technique that was adapted from reference 10 with a refined normalization technique that provides normalization to 20 coronal slices for each data set. All reported volumes were corrected for sex, intracranial volume, and age in a linear regression model as in our previous study. The MATLAB-based “Statistical Toolbox” (The Mathworks Inc., Natick, MA) was used for statistical data analysis. Parametric unpaired 2-sample t tests for unequal variances were used to test for statistical differences between groups, as indicated by Lilliefors tests for normality. All correlations were studied using Spearman rank order correlation coefficient. All statistical tests were 2-sided, and P < 0.05 was considered significant.

Results

Clinical Features

Clinical features are summarized in Table 1. Age, sex, education duration, daytime sleepiness (Epworth Sleepiness Scale), and body mass index were not significantly different between PD and non-PD individuals. Individuals with PD displayed worse cognitive performance (Montreal Cognitive Assessment, Mann-Whitney U test z = -2.16, P = 0.030) compared with non-PD individuals.

Morphometric Analyses of the Hypothalamus

The total hypothalamus volumes in the prospective cohort were normally distributed (Lilliefors test P = 0.10), and the distribution largely overlapped within the same volume range for both groups (Fig. 1a); the volumes for PD (n = 30, V = 921 ± 78 mm³) and healthy non-PD individuals (n = 30, V = 917 ± 67 mm³) did not differ (t = 0.19, P = 0.850). There were also no differences for anterior (t test t = 1.05, P = 0.300) and posterior (t = -0.61, P = 0.543) hypothalamic volumes, respectively, between PD and non-PD individuals. The coronal slice-wise hypothalamic volumetric comparison between PD and non-PD individuals indicated no significant effects (Fig. 1b). There were no significant correlations between the hypothalamus volume and either the Montreal Cognitive Assessment score (r = -0.18, P = 0.360), years of education (r = 0.14, P = 0.500), disease duration (r = 0.13, P = 0.505), Epworth Sleepiness Scale (r = -0.14, P = 0.501), or UPDRS III motor score (r = 0.03, P = 0.903).

To confirm the volumetric findings, a large cohort of PD and healthy non-PD individuals was retrospectively analyzed for volumetric differences of the hypothalamus. The total hypothalamus volumes were normally well distributed (Lilliefors test P ≥ 0.5), largely overlapping between groups and did not differ (t = -0.52, P = 0.602) for PD (n = 202, V = 925 ± 88 mm³, volume range, 671–1153 mm³) and non-PD individuals (n = 100, V = 932 ± 114 mm³, 699–1194 mm³). Coronal slice-wise volumetric comparisons also did not reveal any significant volume difference at the single hypothalamic slice level, so that these results were in full accordance with the prospective study cohort.

Discussion

Using in vivo MRI, there was no statistical difference in hypothalamus size between PD and non-PD individuals for 2 separate cohorts. The involvement of the hypothalamus was demonstrated in PD several decades ago, including evidence from postmortem studies. First, a subset of hypothalamic neurons become selectively targeted during disease, with the tuberomammillary nucleus becoming affected in an early stage of the symptomatic phase, whereas other neuronal populations remain spared. Second, a number of hypothalamic-dependent functions, such as sleep and circadian rhythm, are severely affected by disease progression. This hypothalamic involvement could be secondary to dopaminergic or serotonergic and related to involvement of the autonomic nervous system.

In the current study, despite these repeatedly observed features of hypothalamic involvement by others, we were unable to observe gross atrophy of the hypothalamus. This contrasts with a previous effort by Breen and colleagues, who reported volumetric loss in the hypothalamus. However, our study included more than 230 patients, compared with 12 patients in that study, and we used a different well-established segmentation method for the hypothalamus that overcomes the main challenge of defining its lateral boundaries.

Importantly, when we applied the identical method of hypothalamic volumetry to ALS, we observed a significant hypothalamic atrophy, even in presymptomatic gene carriers, in a large sample of patients similar to what has been documented in FTD patients. Thus, our method is sufficiently sensitive to detect differences in volume when present. We think that this differential involvement of the hypothalamus between ALS and FTD, on the one hand, and PD, on the other, could reflect different mechanisms at work between these different neurodegenerative diseases selectively targeting this brain region. Alternatively, the gradually progressive nature of PD might not result in global hypothalamic atrophy while, at the same time, affecting only discrete sets of neurons and their connectivities. These results suggest hypothalamic volumetry as a possibly specific biomarker for the ALS-FTD spectrum in contrast to PD.

This study was limited by the lack of postmortem validation of hypothalamic involvement and of the diagnoses. The individuals with PD were all medicated because untreated PD patients might otherwise have experienced difficulties leading to discomfort-induced motion artifacts during MRI scans. In addition, different imaging protocols were used for 2 different cohorts, which might be regarded as a confounding factor when
comparing cross-cohort volumetric data. As a further limitation, it has to be noted that only one specific imaging method was used, and the data analyses did not include other potentially more sensitive approaches such as shape analysis. Future (and ideally, autopsy-controlled) studies should examine the microstructure of the hypothalamus in vivo, for example, by diffusion-weighted imaging, and in so doing also address connectome-based analyses of the structural and functional networks of the hypothalamus in PD.

In conclusion, involvement of the hypothalamus in PD as histopathologically evidenced does not appear to be detectable in vivo by using MRI-based volumetric quantification. The results further suggested that the macrostructure of the hypothalamus remains stable throughout the course of PD, and this raises the question of whether the involvement of the hypothalamus might be identifiable in vivo by investigating its microstructure by diffusion-weighted imaging techniques. Heterogeneity in neurodegenerative diseases with potentially different propagation schemes suggests that the link between involvement at the cellular level and the morphometry of the hypothalamus may depend on the specific underlying neurodegenerative process.

Acknowledgments: The authors acknowledge Sonja Fuchs for MRI data acquisition and Ralph Kühne for administrative assistance.

References


Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.